Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival.

Firestein R, Shima K, Nosho K, Irahara N, Baba Y, Bojarski E, Giovannucci EL, Hahn WC, Fuchs CS, Ogino S.

Int J Cancer. 2010 Jun 15;126(12):2863-73. doi: 10.1002/ijc.24908.

2.

TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers.

Shima K, Morikawa T, Yamauchi M, Kuchiba A, Imamura Y, Liao X, Meyerhardt JA, Fuchs CS, Ogino S.

PLoS One. 2011;6(9):e25062. doi: 10.1371/journal.pone.0025062.

3.

Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.

Imamura Y, Lochhead P, Yamauchi M, Kuchiba A, Qian ZR, Liao X, Nishihara R, Jung S, Wu K, Nosho K, Wang YE, Peng S, Bass AJ, Haigis KM, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S.

Mol Cancer. 2014 May 31;13:135. doi: 10.1186/1476-4598-13-135.

4.

Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.

Kure S, Nosho K, Baba Y, Irahara N, Shima K, Ng K, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2765-72. doi: 10.1158/1055-9965.EPI-09-0490.

5.

Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.

Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis KM, Fuchs CS, Ogino S.

Clin Cancer Res. 2012 Sep 1;18(17):4753-63. doi: 10.1158/1078-0432.CCR-11-3210.

6.

SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features.

Li T, Liao X, Lochhead P, Morikawa T, Yamauchi M, Nishihara R, Inamura K, Kim SA, Mima K, Sukawa Y, Kuchiba A, Imamura Y, Baba Y, Shima K, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S, Qian ZR.

Ann Surg Oncol. 2014 Dec;21(13):4164-73. doi: 10.1245/s10434-014-3888-y.

7.

Tumor TP53 expression status, body mass index and prognosis in colorectal cancer.

Morikawa T, Kuchiba A, Liao X, Imamura Y, Yamauchi M, Qian ZR, Nishihara R, Sato K, Meyerhardt JA, Fuchs CS, Ogino S.

Int J Cancer. 2012 Sep 1;131(5):1169-78. doi: 10.1002/ijc.26495.

8.

A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers.

Nosho K, Kure S, Irahara N, Shima K, Baba Y, Spiegelman D, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S.

Gastroenterology. 2009 Nov;137(5):1609-20.e1-3. doi: 10.1053/j.gastro.2009.08.002.

9.

Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers.

Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Meyerhardt JA, Fuchs CS.

J Clin Oncol. 2009 Sep 20;27(27):4591-8. doi: 10.1200/JCO.2009.22.8858.

10.

Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.

Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J, Meyerhardt JA, Hornick JL, Shivdasani RA, Fuchs CS, Ogino S.

Clin Cancer Res. 2009 Jul 15;15(14):4665-73. doi: 10.1158/1078-0432.CCR-09-0401.

11.

Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.

Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, Nosho K, Qian ZR, Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S.

Clin Cancer Res. 2012 Apr 15;18(8):2257-68. doi: 10.1158/1078-0432.CCR-11-2410.

12.
13.

Role of CDK8 and beta-catenin in colorectal adenocarcinoma.

Seo JO, Han SI, Lim SC.

Oncol Rep. 2010 Jul;24(1):285-91.

PMID:
20514474
14.

Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women.

Samadder NJ, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, Lynch CF, Anderson KE, French AJ, Haile RW, Potter JD, Slager SL, Smyrk TC, Thibodeau SN, Cerhan JR, Limburg PJ.

Gastroenterology. 2013 Aug;145(2):348-56.e1-2. doi: 10.1053/j.gastro.2013.05.001.

15.

Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.

Ogino S, Kawasaki T, Kirkner GJ, Ogawa A, Dorfman I, Loda M, Fuchs CS.

J Pathol. 2006 Oct;210(2):147-54.

PMID:
16850502
16.

Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer.

Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Dehari R, Meyerhardt JA, Fuchs CS, Ogino S.

Neoplasia. 2007 Jul;9(7):569-77.

17.

Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.

Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, Hazra A, Hunter DJ, Quackenbush J, Spiegelman D, Giovannucci EL, Fuchs CS, Ogino S.

PLoS One. 2008;3(11):e3698. doi: 10.1371/journal.pone.0003698.

18.

Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer.

Lochhead P, Imamura Y, Morikawa T, Kuchiba A, Yamauchi M, Liao X, Qian ZR, Nishihara R, Wu K, Meyerhardt JA, Fuchs CS, Ogino S.

Eur J Cancer. 2012 Dec;48(18):3405-13. doi: 10.1016/j.ejca.2012.06.021.

19.

A cohort study of p27 localization in colon cancer, body mass index, and patient survival.

Ogino S, Shima K, Nosho K, Irahara N, Baba Y, Wolpin BM, Giovannucci EL, Meyerhardt JA, Fuchs CS.

Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1849-58. doi: 10.1158/1055-9965.EPI-09-0181.

20.

PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.

Baba Y, Nosho K, Shima K, Goessling W, Chan AT, Ng K, Chan JA, Giovannucci EL, Fuchs CS, Ogino S.

Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):822-31. doi: 10.1158/1055-9965.EPI-09-1154.

Items per page

Supplemental Content

Support Center